Argus analyst John Staszak initiated Bio-Techne with a Buy rating and a price target of $185, saying the company looks to be "on track for continued solid revenue growth". The analyst points to strong domestic and international demand for Bio-Techne products, along with added benefits from cost controls, lower corporate tax rates, and acquisitions. Staszak models a 16% long term earnings growth rate, noting that its premium 31.2-times forward earnings valuation relative to historical range of 22-33-times is justified by that project earnings forecast.